ICD-10 Z91.0111 is officially defined as "Allergy to milk products with tolerance to baked milk." code Z91.0111 is referenced in 9 tracked payer policy changes from Blue Cross Blue Shield of North Dakota, UnitedHealthcare, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Z91.0111 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Blue Cross Blue Shield of North Dakota's August 2026 pharmacy update covers Medicaid Expansion medical drug prior authorization policies, with new policies and coding changes effective October 1, 2026. The most important billing change is the new HCPCS codes that replace older codes, such as Q5172 for Filkri and J9362 for Yondelis, plus added diagnosis codes for several drugs; the commercial pharmacy policies were reviewed with no changes listed.
Blue Cross Blue Shield of North Dakota released comprehensive medical policy updates effective June 18, 2026, including new policies for procedures like vagus nerve stimulation and transcatheter aortic valve implantation, revised criteria for multiple existing policies, and extensive billing code additions and removals across various specialties.
UnitedHealthcare Community Plan of Indiana has revised its Xolair (omalizumab) policy effective October 1, 2026, clarifying that provider-administered subcutaneous injections are covered for chronic urticaria, IgE-mediated food allergy, moderate-to-severe persistent asthma, and nasal polyps, while self-administered injections fall under pharmacy benefits. The policy also explicitly identifies conditions where Xolair is NOT covered (seasonal/perennial allergic rhinitis, atopic dermatitis, acute bronchospasm, anaphylaxis). Indiana is now included in coverage (previous policy excluded it).
BCBSND updated diagnosis codes for Allergy Skin Testing effective January 1, 2026. The policy removed codes Z91.011 and Z91.012, and added new codes 0110, Z91.0111, Z91.0112, Z91.0120, Z91.0121, and Z91.0122. This change was supposed to be communicated in January but was missed until now.
Independence Blue Cross updated Medicare Advantage policy MA08.025h to MA08.025i, replacing generic ICD-10 codes for milk and egg allergies (Z91.011, Z91.012) with more specific codes that differentiate between unspecified allergies and those with tolerance or reactivity to baked products. This change affects diagnosis code reporting for omalizumab coverage claims but does not alter coverage criteria or medical necessity requirements.
Independence Blue Cross updated ICD-10 diagnosis codes for Omalizumab (Xolair) coverage effective 10/01/2025. Removed two non-specific allergy codes (Z91.011, Z91.012) and added six more granular codes that distinguish between unspecified allergies and those with tolerance/reactivity to baked milk and eggs. Billing teams must update claim submission systems and encounter forms to use the new specific ICD-10 codes to avoid claim denials.
Allergen immunotherapy is paid by injection, not by dose, and provision of antigens is paid by dose or vial based on the CPT descriptor. Immunotherapy is considered medically necessary in patients with demonstrated hypersensitivity that cannot be managed by medications or avoidance. Sublingual immunotherapy, provocative and neutralization therapy for food allergies using intradermal and subcutaneous routes, urine autoinjections, and repository emulsion therapy are investigational and not covered. Clinical ecology services are investigational even when billed as allergy services, and allergen-proof supplies such as mattresses, pillows and air purification devices are considered personal convenience items.
Independence Blue Cross updated MA08.025h to MA08.025i, replacing generic ICD-10 allergy codes (Z91.011, Z91.012) with more specific granular codes that differentiate between unspecified allergies and those with tolerance or reactivity to baked products. This change affects diagnosis code reporting for omalizumab claims but does not alter coverage criteria or billing codes.
Independence Blue Cross updated policy 08.00.55m to 08.00.55n, replacing six general ICD-10 allergy codes with twelve more specific codes that distinguish between unspecified allergies and those with tolerance/reactivity to baked milk and eggs. This affects diagnosis code reporting for omalizumab claims but does not change coverage criteria, billing codes, or reimbursement rates.
Watch Z91.0111
Get one email when a payer policy names Z91.0111, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.